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Chronic  lymphocytic  leukemia  (CLL)  is  the 
most common adult leukemia in the Western 
world (Chiorazzi et al., 2005; Tam and Keating, 
2010; Zenz et al., 2010b). CLL is characterized 
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The pathogenesis of chronic lymphocytic leukemia (CLL), the most common leukemia in adults, is 
still largely unknown. The full spectrum of genetic lesions that are present in the CLL genome, and 
therefore the number and identity of dysregulated cellular pathways, have not been identified. By 
combining next-generation sequencing and copy number analysis, we show here that the typical 
CLL coding genome contains <20 clonally represented gene alterations/case, including predomi-
nantly nonsilent mutations, and fewer copy number aberrations. These analyses led to the discov-
ery of several genes not previously known to be altered in CLL. Although most of these genes were 
affected at low frequency in an expanded CLL screening cohort, mutational activation of NOTCH1, 
observed in 8.3% of CLL at diagnosis, was detected at significantly higher frequency during 
disease progression toward Richter transformation (31.0%), as well as in chemorefractory CLL 
(20.8%). Consistent with the association of NOTCH1 mutations with clinically aggressive forms of 
the disease, NOTCH1 activation at CLL diagnosis emerged as an independent predictor of poor 
survival. These results provide initial data on the complexity of the CLL coding genome and iden-
tify a dysregulated pathway of diagnostic and therapeutic relevance.
© 2011 Fabbri et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it  is  available  under  a  Creative  Commons  License  (Attribution–Noncommer-
cial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
by a marked degree of clinical heterogeneity, 
ranging from patients that harbor a highly sta­
ble disease with a nearly normal life expectancy, 
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NOTCH1 undergoes multiple proteolytic cleavages that 
allow its intracellular portion to translocate to the nucleus, thus 
leading to transcriptional activation of multiple target genes, 
including MYC (Palomero et al., 2006). In T cell acute lympho­
blastic leukemia (T­ALL), activating mutations of NOTCH1  
are the predominant genetic alteration, accounting for up to 
60% of the cases (Weng et al., 2004). The present study docu­
ments a high frequency of NOTCH1 mutations in aggressive 
clinical phases of CLL, exemplified by RS transformation and 
chemorefractoriness, and identifies NOTCH1 alterations as 
an independent predictor of poor prognosis.
RESULTS
Mutational load by exome sequencing analysis
To identify somatic gene alterations associated with CLL 
pathogenesis and to gain insights into the overall complexity 
of the CLL coding genome, we performed exome capture 
and next generation sequencing analysis of paired tumor and 
normal DNAs from 5 newly diagnosed, previously untreated 
CLL patients (Table S1, discovery panel; and Fig. S1). We also 
analyzed by direct sequencing the coding exons of NOTCH1, 
as this gene has been previously implicated in the disease 
(Sportoletti et al., 2010), but was not represented in the cap­
ture array.
Validation of the candidate variants by Sanger sequencing 
in the same samples confirmed the presence of 40 somatic, non­
silent mutations involving 39 distinct genes, with NOTCH1 
representing the only recurrently mutated one (n = 2/5 cases; 
Table S2, Table S3, and Supplemental Results). Most of the 
mutations detected by this approach appeared to be repre­
sented in a predominant clone, based on the presence of a 
clear peak in the chromatogram. The overall mutation load 
was homogeneous across the five cases (mean = 8, range =   
6–10 lesions/case) and included 36 single nucleotide substitu­
tions (n = 32 aa changes and 4 premature stop codons) and   
4 frameshift insertions/deletions (Fig. 1 a and Table S3).   
Although assessed on a limited number of events, the mutational 
spectrum of CLL was analogous to that reported in other 
cancer types (e.g., colorectal, pancreatic, and brain tumors; 
Greenman et al., 2007; Jones et al., 2008; Parsons et al., 2011), 
with a predominance of transitions over transversions (n = 
25:11, ratio 2.2) a preferential targeting of G and C nucleo­
tides (69.4 vs. 30.6%, affecting A/T nucleotides), and a bias for 
mutations at 5­CpG­3 dinucleotides (P < 0.001; Fig. S2).
Genome-wide SNP analysis
Analysis  of  the  same  5  CLL  samples  (and  paired  normal 
DNAs) by the Affymetrix SNP 6.0 platform revealed a total 
of 12 somatic copy number alterations (CNA), with an aver­
age of 2.4 lesions per case (range: 1–5; Table S4). 10 of these 
regions harbored genetic elements, including protein coding 
genes and/or noncoding RNA genes, and 5 of them encom­
passed <3 genes that, because of their focal involvement, rep­
resent the likely targets of the aberration (Fig. 1 b). Consistent 
with previous studies (Kujawski et al., 2008; Grubor et al., 
2009), the majority of the observed lesions were represented 
to patients with a rapidly progressive disease that are destined 
to shortly succumb (Chiorazzi et al., 2005; Tam and Keating, 
2010;  Zenz  et  al.,  2010b). The  variable  course  of  CLL  is 
driven, at least in part, by heterogeneity in the leukemia biol­
ogy (Tam and Keating, 2010; Zenz et al., 2010b). A fraction of 
CLL is prone to transformation to diffuse large B cell lym­
phoma (DLBCL), a condition known as Richter syndrome 
(RS) that is characterized by a rapidly deteriorating clinical 
course with an extremely dismal outcome (Tsimberidou and 
Keating, 2005; Rossi and Gaidano, 2009).
The molecular pathogenesis of CLL is not fully under­
stood. In contrast to other B cell malignancies, CLL is not as­
sociated with recurrent balanced chromosomal translocations 
(Klein and Dalla­Favera, 2010). Deletion of 13q14 affecting 
the DLEU2/MIR15-16 cluster is conceivably the initiating 
lesion in nearly 50% of CLL cases, followed by the accumula­
tion of additional alterations during tumor progression, namely 
del17p13 and del11q22–q23 affecting TP53 and ATM, re­
spectively (Döhner et al., 2000; Calin et al., 2002; Klein et al., 
2010; Zenz et al., 2010b). Rare NOTCH1 mutations have 
been sporadically reported (Sportoletti et al., 2010).
These known genetic lesions, however, do not fully reca­
pitulate the molecular pathogenesis of CLL and do not en­
tirely explain the marked clinical heterogeneity of the disease 
or the development of severe complications, such as RS trans­
formation and chemorefractoriness, which, despite recent ad­
vances, still represent unmet clinical needs (Rossi and Gaidano, 
2009; Tam and Keating, 2010; Zenz et al., 2010b; Fangazio   
et al., 2011). In the instance of CLL transformation, TP53 
disruption and MYC alterations are observed in up to 50% of 
RS cases, but the genetic lesions of the remaining 50% are 
virtually unknown (Rossi et al., 2011). Also, TP53 disruption 
is observed in 40% of CLL cases refractory to therapy, but the 
molecular basis of the remaining 60% CLL is unknown (Zenz 
et al., 2010a).
Genome­wide methods aimed at the characterization of 
the entire spectrum of genetic lesions present in the CLL ge­
nome may be useful to provide further insights into CLL 
pathogenesis, and might contribute to elucidate the molecular 
basis of CLL clinical evolution, including RS transformation 
and development of chemorefractoriness. On these grounds, 
we have exploited an integrated approach based on next gen­
eration whole­exome sequencing (WES) and genome­wide 
high­density single­nucleotide polymorphism (SNP) analysis 
to investigate the CLL coding genome. We report that CLL is 
characterized by a limited number of structural genetic alter­
ations compared with other B cell malignancies, and carries a 
restricted number of mutations in genes potentially relevant 
for CLL pathogenesis.
Among  the  genes  found  mutated  in  CLL,  NOTCH1 
emerged as a highly recurrent target of genetic lesions in   
specific phases of the disease. NOTCH1 encodes a class I trans­
membrane protein functioning as a ligand­activated transcrip­
tion factor and playing an important role in cell differentiation, 
proliferation, and apoptosis (Grabher et al., 2006; Aster et al., 
2008, 2011; Paganin and Ferrando, 2011). Upon ligand­binding, JEM Vol. 208, No. 7 
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myeloma (Chapman et al., 2011), and in DLBCL (unpublished 
data). Conversely, this load is comparable to that reported in 
acute myeloid leukemia (Mardis et al., 2009) and in pediatric 
medulloblastoma (Parsons et al., 2011). This observation, to­
gether with the low number of CNAs in general, and whole 
chromosome alterations in particular, suggests that the CLL 
genome is relatively stable and homogeneous in terms of mu­
tational load, ploidy, and large chromosomal rearrangements.
Identification of frequently mutated genes
The genes found to be mutated by the aforementioned ap­
proach include 32 genes listed in the Catalogue of Somatic 
Mutations in Cancer database and previously found to be 
mutated in other cancer genomes (Table S3; Forbes et al., 
2011). Although the functional significance of the missense 
mutations affecting these genes is largely unknown, 22 out of 
32 (68.8%) are expected to alter the function of the encoded 
protein, based on the Polyphen­2 prediction algorithm (Table 
S3; Adzhubei  et  al.,  2010). The  Gene  Ontology  database 
(http://www.geneontology.org/) revealed that one third of the 
identified mutated genes are involved in transcriptional regula­
tion and chromatin remodeling processes (n = 13/39, 33.3%).
One criterion to assess the pathogenic relevance of the 
observed genetic lesions is to examine their recurrence in 
the disease. In the discovery panel, NOTCH1 was the only 
gene mutated in more than one patient (2/5 cases); however, 
the lack of recurrence in other mutated genes may be as­
cribed to the limited number of cases investigated. We there­
fore  expanded  the  mutational  analysis  to  an  independent 
screening  panel  of  48  CLL  cases  with  available  matched 
germline DNA (see Table S5 for the detailed characterization 
of the CLL screening panel). This panel was representative of 
both the IGHV mutated (n = 24) and unmutated (n = 24) 
disease categories. The entire coding region and splice sites of 
the genes found mutated in the discovery panel were studied 
in the screening phase. This analysis, combined with the re­
sults obtained in the 5 cases belonging to the discovery panel, 
revealed the presence of recurrent mutations (n ≥ 2) in   
4 genes, i.e., TGM7, BIRC3, PLEKHG5 (all mutated in ≤5% of 
cases), and NOTCH1 (mutated in 15.1% of cases; Fig. 2).   
by deletions (11/12, 91.7%), ranging in size from 1.3 kb to 
loss of a large portion of a chromosomal arm, as in CLL1 that 
carried a del11q. Deletion of 13q14 was the only recurrent 
lesion, while trisomy 12 (CLL4) represented the only region 
of gain (Fig. S3).
Importantly, the SNP array approach successfully identi­
fied all four lesions previously detected by FISH analysis and 
known to associate with CLL, including two del13q14 (CLL2 
and CLL5), one trisomy 12 (CLL4), and one del11q (CLL1; 
Fig. S3). In both instances, del13q14 encompassed the DLEU2/
MIR15-16 locus along with 61–68 additional genetic elements, 
including the RB1 gene. The del11q spanned more than 100 
genes, including the tumor suppressor ATM and the negative 
regulator of the noncanonical NF­B pathway BIRC3.
Overall complexity of the CLL coding genome
The integration between WES and copy number data pro­
vided a total of 52 genetic lesions, ranging from 7 to 13 le­
sions per case (average = 10.4) and mostly represented by 
point mutations (Fig. 1 c). Even after considering that some 
mutations may have been missed because of limited probe 
density or sequence coverage of the SNP and exome se­
quencing platforms, this mutation burden is 5–20 times lower 
than that observed in solid tumor genomes (Jones et al., 2008; 
Pleasance et al., 2010a; Pleasance et al., 2010b), in multiple 
Figure 1.  Overall load of genetic lesions in CLL. (a) Frequency of 
Sanger-validated somatic nonsilent mutations identified through WES in 
the five CLL discovery cases. (b) Overall frequency of somatically acquired 
CNA according to aberration type in the 5 CLL discovery cases. (c) Com-
bined load of somatically acquired nonsilent mutations and CNA identi-
fied in the CLL discovery panel. CN, copy number.
Figure 2.  Recurrent mutations in CLL. Percentage of CLL primary 
cases harboring mutations in candidate genes after targeted resequenc-
ing of an expanded screening dataset (n = 48 CLL cases). The final number 
of mutated cases over total analyzed (including the 5 discovery CLL) for 
each gene is as follows: NOTCH1, 8/53; TP53, 4/53; PLEKHG5, 2/53; TGM7, 
2/53; BIRC3, 2/53.1392 The CLL coding genome | Fabbri et al.
protein between the third BIR domain and the CARD   
domain. FISH analysis showed loss of the second BIRC3 allele, 
indicating biallelic inactivation in this case as well, thus sug­
gesting a tumor suppressor role for BIRC3 in modulating 
NF­B activation. Interestingly, another CLL case (CLL5 in 
the discovery panel) harbored a missense mutation of the 
MYD88 gene, which encodes an adaptor protein involved in 
Toll­like receptor signaling and in activation of NF­B. The 
same mutation found in case CLL5 (L265P) was recently re­
ported  in  a  large  fraction  of ABC­DLBCL,  where  it  was 
shown to be oncogenically active (Ngo et al., 2011). Finally, 
two cases (CLL4 and CLL13) displayed missense mutations of 
PLEKHG5, a member of the G protein family that has been 
suggested to be involved in NF­B activation (Maystadt et al., 
2007). Collectively, these findings suggest that activation of 
NF­B may be implicated in at least a fraction of CLL cases.
The recurrence of NOTCH1 mutations (15.1%) appeared 
potentially relevant, given the well­established involvement of 
this gene in the pathogenesis of T­ALL and its previously re­
ported association with CLL at low frequency (Weng et al., 2004; 
Although absent in the discovery panel, mutations of TP53 
were also tested in the CLL screening panel, as this genetic lesion 
is known to be recurrent in CLL (Zenz et al., 2010c). This analy­
sis revealed TP53 missense mutations in 4/53 (7.5%) patients.
Although the role of the two missense mutations found in 
the TGM7 gene, which encodes a transglutaminase of unclear 
specific function, remains to be determined, other mutations 
provide preliminary evidence of functional significance. BIRC3, 
a negative regulator of the noncanonical NF­B pathway that 
is  affected  by  chromosomal  translocations  in  MALT  lym­
phoma and by focal deletions in multiple myeloma (Zhou   
et al., 2005; Annunziata et al., 2007; Keats et al., 2007; Rosebeck 
et al., 2011), was biallelically inactivated in CLL1. In this pa­
tient, a copy number loss was observed together with a frame­
shift  deletion  located  between  the  third  baculovirus  IAP 
repeat (BIR) and the caspase activation and recruitment do­
main (CARD), leading to removal of the RING domain, 
which is required for the inhibitory function of BIRC3 (Gyrd­
Hansen and Meier, 2010). A second case (CLL45) harbored a 
nonsense  mutation  (E424X)  truncating  the  corresponding 
Figure 3.  NOTCH1 is mutated in a large fraction of RS cases and chemorefractory CLL. (a) Schematic diagram of the NOTCH1 gene (top) and 
protein (bottom), with its conserved functional domains (EGF-like repeats; LNR, LIN-12/NOTCH repeats; HD, heterodimerization; TM, transmembrane; Ank, 
Ankyrin repeats; TAD, transactivation; PEST). Color-coded shapes indicate the position of the mutations found in CLL at diagnosis, RS, and chemorefrac-
tory CLL. (b) Prevalence of NOTCH1 mutations in CLL at diagnosis, RS, chemorefractory CLL, and de novo DLBCL; numbers on top indicate the actual num-
ber of mutated samples over total analyzed. ***, P < 0.001; **, P < 0.05.JEM Vol. 208, No. 7 
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TFS,  128.5  mo;  P  <  0.001;  Fig.  4). Also,  CLL  harboring 
NOTCH1 mutations were characterized by a significantly 
shorter OS (median OS, 93.8 mo; 5­yr OS, 53.3%) compared 
with  wild­type  CLL  (median  OS  not  reached;  5­yr  OS, 
86.0%;  P  =  0.001;  Fig.  4).  By  multivariate  Cox  analysis, 
NOTCH1 mutations were a predictor of poor OS (HR, 10.1; 
95% CI, 2.6–39.0; P = 0.001) independent of confounding 
covariates, including TP53 disruption (HR, 4.6; 95% CI, 1.6–
13.1; P = 0.004) and unmutated IGHV genes (HR, 6.2; 95% 
CI, 1.4–25.9; P = 0.012).
Collectively, these results confirm previous findings on 
the low frequency and prognostic relevance of NOTCH1 
mutations at CLL diagnosis (Di Ianni et al., 2009; Sportoletti 
et al., 2010), but identify NOTCH1 mutations as a predic­
tor of unfavorable outcome independent of other biologi­
cal features of CLL, namely IGHV mutation status and 
TP53 disruption.
Frequent activating mutations of NOTCH1 in RS
The association between NOTCH1 mutations at CLL diag­
nosis and unfavorable outcome prompted the investigation of 
this gene in patients whose disease subsequently acquired a 
high­risk clinical phenotype. As a model of CLL clinical pro­
gression, we initially chose RS transformation because: (a) it 
represents the most aggressive phase of the clinical spectrum 
of CLL, as also documented by the fact that RS is rapidly le­
thal in most patients; (b) the molecular lesions driving CLL 
transformation to RS are not fully understood (Tsimberidou 
and Keating, 2005; Rossi and Gaidano, 2009; Fangazio et al., 
2011; Rossi et al., 2011).
Based on this rationale, NOTCH1 mutations were ana­
lyzed in the diagnostic biopsy of 58 cases of histologically 
proven RS, all represented by DLBCL transformed from a 
previous CLL phase. The clinical and biological characteristics 
of the RS cases are summarized in Table S8. A total of 19   
Sulis et al., 2008; Sportoletti et al., 2010). This finding, together 
with the preliminary observation of NOTCH1 mutations in 
a few cases of RS (see following paragraph), prompted a system­
atic analysis of NOTCH1 in different clinical phases of CLL.
NOTCH1 mutations at CLL diagnosis occur at low frequency 
and predict poor outcome
To  define  the  frequency  of  NOTCH1  mutations  at  CLL   
diagnosis, we analyzed a consecutive cohort of CLL patients 
(n = 120) sampled at diagnosis and followed at the Amedeo 
Avogadro University of Eastern Piedmont (extension panel). 
This cohort was representative of the main clinical character­
istics of the disease at diagnosis (Table S6). Specifically, IGHV 
homology  ≥98%  occurred  in  39/120  (32.5%)  patients, 
del13q14 was observed in 61/112 (54.5%) cases, normal FISH 
in 32/112 (28.6%), trisomy 12 in 17/112 (15.2%), del11q22­
q23 in 8/112 (7.1%), and TP53 disruption by mutation and/or 
deletion in 13/117 (11.1%; Table S6). After a median follow up 
of 70.3 mo, the 5­yr treatment free survival (TFS) probability 
of the CLL cohort was 60.0% and the 5­yr overall survival 
(OS) probability was 83.3%.
At CLL diagnosis, mutations of NOTCH1 were identified 
in 10/120 (8.3%) patients, all of which displayed a recurrent 
2­bp frameshift deletion (CT7544­7545, P2515fs) that is 
predicted to cause NOTCH1­impaired degradation through 
the truncation of the C­terminal PEST domain (Fig. 3 a and 
Table S7; Weng et al., 2004). NOTCH1 mutations clustered 
with CLL harboring unfavorable features, including unmu­
tated IGHV genes (7/39, 17.9% vs. 3/81, 3.7% in IGHV  
mutated CLL; P = 0.013), and TP53 disruption (3/13, 23.1% 
vs. 7/104, 6.7% in TP53 wild­type CLL; P = 0.047). Consis­
tently, CLL harboring NOTCH1 mutations were character­
ized by a significantly shorter time to progression to a disease 
requiring treatment (median TFS, 7.9 mo) compared with 
CLL  cases  harboring  wild­type  NOTCH1  alleles  (median 
Figure 4.  Kaplan-Meier estimates of treatment-free survival (TFS) and overall survival (OS), according to the mutational status of NOTCH1.1394 The CLL coding genome | Fabbri et al.
phase were already present at subclonal levels in the paired 
CLL phase. To obtain a more quantitative estimate of the 
clonal representation of NOTCH1 mutated versus germline 
alleles, the CLL and RS phases from case RS63 were sub­
jected to ultradeep next generation sequencing (sequencing 
depth 5,000 per sample) using the Roche 454 technology. 
This  approach  showed  that  the  CT7544­7545  (P2515fs) 
mutation, occurring in 58.6% (3,304/5,642) of the sequenc­
ing reads obtained from the RS phase, was restricted to 5.3% 
(239/4524) of the reads obtained at the time of CLL diagno­
sis (Fig. 5 b, Fig. S4, and Fig. S5), indicating an 11­fold in­
crease during the 30­mo interval between CLL diagnosis and 
RS development. These data suggest that clonally represented 
mutations of RS might already be present years before RS 
transformation, and that the clone harboring the mutation is 
progressively selected during the CLL clinical history ending 
into RS transformation.
One RS patient (RS86) carrying a NOTCH1 mutation 
disrupting the PEST domain (CT7544­7545, P2515fs) in 
the CLL phase and in a first RS biopsy, subsequently acquired 
a second NOTCH1 mutation (G5164A, V1722M) affecting 
the heterodimerization domain when RS further progressed 
from nodal localization to peripheral blood invasion. The   
detection of PEST and heterodimerization domain mutations 
occurring in the same patient is of relevance, as mutations in 
these two distinct domains have been shown to act synergistically   
mutations were identified in 18/58 (31.0%) cases (Table S7). 
The frequency of NOTCH1 mutations in RS was signifi­
cantly higher compared with the frequency observed at CLL 
diagnosis  in  the  consecutive  series  (P  <  0.001;  Fig.  3b). 
NOTCH1 mutations in RS were represented by a recurrent 
2­bp frameshift deletion (CT7544­7545, P2515fs; n = 15), 
one frameshift insertion, and two nonsense mutations (Fig. 3 a). 
On the basis of their distribution along the NOTCH1 pro­
tein, all frameshift and nonsense mutations of NOTCH1 are 
predicted to cause NOTCH1­impaired degradation through 
the truncation of the C­terminal PEST domain (Table S7 and 
Fig. 3 a). One single mutation (G5164A, V1722M) affected 
the heterodimerization domain of NOTCH1 (Fig. 3 a).
To establish the timing of acquisition of NOTCH1 muta­
tions during the clinical history of RS patients, we investi­
gated paired sequential samples collected at the time of CLL 
diagnosis. 15 patients harboring 16 NOTCH1 mutations and 
belonging to the RS series were analyzed by this approach. 
Of the 16 NOTCH1 mutations observed in the RS phase,   
5 (31.3%) were not detectable in the paired CLL phase within 
the sensitivity threshold of Sanger sequencing (Fig. 5 a). Con­
versely, 6/16 (37.5%) mutations detected in the RS phase 
were already present at the time of CLL diagnosis, where their 
clonal representation appeared to be similar to that observed 
in RS, as estimated by Sanger sequencing (Fig. 5 a). Interest­
ingly, 5/16 (31.2%) NOTCH1 mutations identified in the RS 
Figure 5.  Timing of NOTCH1 mutations in RS. (a) NOTCH1 mutations in some cases of RS are not identifiable in the preceding CLL phase, whereas in 
other patients may already be present before transformation, at a clonal/subclonal level. In the heatmap, rows correspond to NOTCH1 mutations and 
columns represent sequential phases of the disease (paired CLL diagnostic samples and RS samples), color-coded based on the mutational status. (b) The 
NOTCH1 mutation detected in RS case RS63 is present at subclonal levels at the time of CLL diagnosis (sample CLL63). The graph shows a quantitative 
estimate of the balance between wild-type and mutated (CT7544-7545) NOTCH1 alleles assessed by ultradeep 454 sequencing in the paired CLL-RS 
samples (CLL63 and RS63). 30 mo elapsed between collection of the CLL sample (diagnosis of CLL) and collection of the RS sample (obtained at diagnosis 
of RS). Numbers on top indicate the actual number of sequencing reads carrying the mutations over total analyzed (for details, see Materials and meth-
ods). (c) Mutations of NOTCH1 are largely mutually exclusive with MYC activating events (translocations and copy number gains) in RS. In the heatmap, 
rows correspond to the indicated genes, and columns represent individual RS samples, color-coded based on the gene status (white, wild-type; red, mu-
tated or activated or disrupted).JEM Vol. 208, No. 7 
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hypothesized that NOTCH1 mutations might also provide a 
marker of chemorefractoriness in patients who clinically pro­
gressed because of treatment failure without transformation 
to RS. To address this issue, NOTCH1 mutations were inves­
tigated in 48 cases of progressive and chemorefractory CLL in 
which RS had been ruled out based on clinical picture, lymph 
node biopsy, and/or 18FDG­PET studies (Table S9). Samples 
from these cases were obtained at the time of progression im­
mediately before starting the treatment to which the patient 
eventually  failed  to  respond.  Mutations  were  identified  in 
10/48 (20.8%) cases of chemorefractory CLL (Table S7), in­
cluding 8/35 (22.8%) fludarabine­refractory and 2/13 (15.3%) 
alkylator­refractory cases. The frequency of NOTCH1 muta­
tions in chemorefractory CLL was significantly higher com­
pared with the frequency observed at CLL diagnosis in the 
consecutive series (P = 0.033; Fig. 3 b). All mutations led to a 
shift in the reading frame and, as observed in RS, were mostly 
(8/10) represented by the 2­bp frameshift deletion CT7544­
7545 (P2515fs). On the basis of their distribution along the 
NOTCH1 protein, mutations observed in chemorefractory 
CLL are all predicted to increase NOTCH1 stability via 
truncation of the C­terminal PEST domain (Fig. 3 a; Weng   
et al., 2004).
In CLL, the molecular mechanisms of chemorefractori­
ness are represented by TP53 disruption in up to 40% of cases, 
indicating that other currently unknown mechanisms might 
be operative in the remaining 60% of cases. In the current se­
ries of chemorefractory CLL, TP53 was disrupted by muta­
tions  and/or  deletions  in  19/48  (39.6%)  cases.  NOTCH1 
mutations occurred in 6/29 (20.7%) TP53 wild­type chemo­
refractory CLL, whereas they overlapped with TP53 disrup­
tion in 4/19 cases (21.1%).
Based on these data, NOTCH1 mutations represent a fre­
quent genetic lesion of CLL associated with progressive dis­
ease failing treatment.
DISCUSSION
The goal of this study was to characterize the nature and fre­
quency of somatic genetic alterations affecting the CLL cod­
ing  genome  by  integrating  the  analysis  of  structural  and 
sequence mutations of DNA. This combined approach has 
allowed the definition of the degree of complexity charac­
terizing the CLL coding genome, with implications for the 
mechanisms leading to genetic alterations in this disease. This 
analysis has also revealed the involvement of the NOTCH1 
pathway in disease progression and transformation, with diag­
nostic and therapeutic implications.
Although analysis of larger cohorts of patients will be re­
quired to conclusively assess the precise number of genetic 
lesions that are present in the CLL genome, the combined set 
of gene alterations (i.e., copy number changes and mutations) 
identified in the CLL discovery panel provides initial infor­
mation about the order of magnitude of the lesions associated 
with this disease. Given the presence of 8 nonsilent muta­
tions and 2 CNAs per CLL case, our results suggest that the 
in promoting NOTCH1 signaling activation (Weng et al., 
2004). The progressive accumulation of multiple NOTCH1 mu­
tations during clinical history further reinforces the notion that 
NOTCH1 activation might be relevant for CLL progression.
The occurrence of NOTCH1 activation in RS was then 
compared with the distribution of other genetic alterations 
that are recurrently associated with this disease. MYC, one of 
the target genes and major downstream effectors of NOTCH1 
(Palomero et al., 2006; Li et al., 2011), was targeted by trans­
locations in 9/51 (17.6%) RS cases and by gene amplification 
in 2 additional cases. NOTCH1 mutations and MYC abnor­
malities distributed in a mutually exclusive fashion (Fig. 5 c), 
although  at  borderline  statistical  significance  (P  =  0.076), 
conceivably because of the limited number of cases included 
in the analysis. On these bases, by combining NOTCH1  
mutations and MYC abnormalities, 26/51 (51.0%) RS harbor 
genetic lesions ultimately leading to MYC activation. Among 
CLL, MYC abnormalities were extremely rare (1/120; 0.8%), 
in agreement with the notion that they are generally acquired 
at RS transformation (Huh et al., 2008; Rossi et al., 2011). 
The sole case of CLL carrying a MYC alteration was devoid 
of NOTCH1 mutations.
TP53 was disrupted by mutations and/or deletion of the 
locus in 30/54 (55.5%) RS. TP53 disruption frequently paired 
with NOTCH1 mutations (8/16, 50%) and MYC abnormali­
ties (7/11, 63.6%) in the same RS sample, thus contributing 
to a dual­hit genetic mechanism of transformation (Fig. 5 c).
All cases of RS included in this study were histologically 
classified as DLBCL, a pathological entity characterized by 
high molecular heterogeneity that may arise either de novo or 
upon transformation from an indolent B cell malignancy, as in 
the case of CLL transformation to RS (Swerdlow, 2008). To 
assess the specificity of NOTCH1 mutations for RS, 134 cases 
of  de  novo  DLBCL  were  also  investigated.  Mutations  of 
NOTCH1 were very rare in this category, being restricted to 
2/134 (1.5%) cases (Table S7 and Fig. 3 b).
The frequent recurrence of NOTCH1 mutations in RS 
prompted the investigation of other NOTCH1­related genes, 
namely NOTCH2 and FBXW7 (O’Neil et al., 2007; Thompson 
et al., 2007; Lee et al., 2009). Mutations of NOTCH2 were 
detected in 2/32 (6.2%) cases of RS, and included one amino 
acid change (K2121N), that was shown to be acquired at 
transformation, and a premature stop codon (R2400*; in this 
case, no material was available from the corresponding diag­
nostic CLL sample). FBXW7 mutations scores were consis­
tently negative (0/32).
Overall, these data document that mutations activating 
the Notch pathway are a frequent event in the pathogenesis 
of RS. In the context of the clinicopathological spectrum of 
DLBCL subtypes, NOTCH1 mutations appear to preferen­
tially associate with transformed cases.
Frequent activating mutations of NOTCH1  
in chemorefractory CLL
Because RS is a highly chemorefractory condition (Rossi 
and Gaidano, 2009; Tsimberidou and Keating, 2005), we   1396 The CLL coding genome | Fabbri et al.
support  of  this  notion  is  the  observation  of  three  lesions 
(BIRC3, MYD88, and PLEKHG5) each detected at very low 
frequency, yet all linked to perturbation of the NF­B activ­
ity, a  well­documented oncogenic pathway (Staudt,  2010). 
Each of the genetic alterations observed in this initial study 
represents the basis for extensive analysis of additional lesions 
in their respective cellular pathways.
A novel finding emerging form this study is the associa­
tion between somatic mutations of NOTCH1 and different 
aspects of disease progression. The mutations observed in CLL 
have consequences on NOTCH1 function that have been 
documented in T­ALL, where their oncogenic activity has 
been extensively demonstrated in vitro and in vivo (Weng   
et al., 2004; O’Neil et al., 2006). In fact, the presence of 
NOTCH1 mutations in rare cases of CLL at diagnosis has 
been previously reported and is confirmed in our study 
(Di Ianni et al., 2009; Sportoletti et al., 2010). Conversely, the 
association of these mutations at a significantly higher fre­
quency with both RS and CLL investigated at the time of 
chemorefractoriness strongly suggests that NOTCH1 muta­
tions are selected during disease progression. At CLL diagnosis, 
NOTCH1 mutations identify a disease subgroup enriched for 
poor risk genetic features, and characterized by an aggressive 
clinical phenotype. Future investigations involving large and 
prospective CLL cohorts are required to show how NOTCH1 
mutations interact with other high­risk genetic features.
In the case of RS, our data cannot conclusively distinguish 
whether NOTCH1 mutations are already present at subclonal 
levels early during CLL development and are subsequently 
selected (as demonstrated for a few cases), or whether they 
are acquired de novo during disease transformation to RS. 
A conclusive demonstration of the precise timing of NOTCH1 
mutations in RS awaits studies aimed at tracking NOTCH1 
mutations with high sensitivity techniques in disease phases 
preceding RS development (Campbell et al., 2008). Also, the 
recurrent presence of NOTCH1 mutations in chemorefrac­
tory CLL might be caused either by selection of more malig­
nant clones during disease progression or by a role of these 
mutations in determining drug resistance. This issue may be 
addressed  by  dedicated  studies  of  NOTCH1  mutations  in 
prospective cohorts of CLL, ideally in the context of con­
trolled clinical trials.
Concerning the pathogenesis of RS, our results show that 
NOTCH1 mutations are largely mutually exclusive with MYC 
oncogenic activation. This finding is consistent with the ob­
servation that NOTCH1 directly stimulates MYC transcription 
and suggests that activation of oncogenic MYC may be one 
common final pathway selected for tumorigenesis (Palomero   
et al., 2006). Conversely, both NOTCH1 mutational activa­
tion and MYC deregulation often coexist with inactivation of 
the TP53 tumor suppressor gene, an event that is commonly 
observed in association with MYC activation in tumors, which 
may be selected to prevent the apoptotic effects and the re­
sponse to genomic instability both induced by MYC over­
expression  (Eischen  et  al.,  1999;  Schmitt  et  al.,  2002; 
Dominguez­Sola et al., 2007; Rossi et al., 2011).
coding genome of CLL harbors at least 10 potentially relevant 
genetic aberrations. As an additional 40% of nonsilent mu­
tations may have escaped detection by the WES approach 
used, because of relatively low depth of coverage, the total 
number of gene alterations present in a CLL genome may be 
<20. This estimate refers to those lesions that are clonally rep­
resented in the CLL genome at diagnosis, and which may 
have thus contributed to the malignant transformation pro­
cess. As such, this preliminary CLL genome picture may serve 
as an initial database for the determination of frequency in 
additional panel of cases.
The order of magnitude of lesions detected in the coding 
genome  of  CLL  appears  considerably  lower  than  that  re­
ported for common epithelial cancers. Among hematologic 
malignancies, the complexity of the CLL genome is also on 
the lower side, markedly smaller than that of DLBCL (<100) 
and multiple myeloma (50), and comparable to that of some 
acute leukemias (10; Ley et al., 2008; Mardis et al., 2009; 
Chapman et al., 2011; unpublished data). The predominance 
of point mutations over CNAs is notable, as it is unusual com­
pared with most cancer types (Mullighan et al., 2007; Lenz   
et al., 2008; Parsons et al., 2011). This observation, together 
with the well­documented rarity of reciprocal balanced chro­
mosomal translocations in CLL (Klein and Dalla­Favera, 
2010), is consistent with previous models suggesting a deriva­
tion from a B cell counterpart in which immunoglobulin 
gene remodeling mechanisms are not active and those con­
trolling ploidy remain intact.
On  the  other  hand,  similar  to  most  cancer  types  are:   
(a) the observed predominance of transitions over transver­
sions; (b) the preferential targeting of C:G and G:C base pairs; 
and (c) the significant bias toward alterations at CpG dinucle­
otides. The distribution of the mutations along the entire span 
of transcribed regions does not seem to reflect the abnormal 
and/or ectopic activity of members belonging to the APO­
BEC family of deaminases, including activation induced de­
aminase (Albesiano et al., 2003; Delker et al., 2009), which 
targets the 5 portion of genes within 2 kb from the tran­
scription initiation site. Instead, the observed pattern of alter­
ations is more consistent with a derivation from endogenous 
biochemical processes, such as the spontaneous deamination 
of 5­methylcytosine residues (Parsons et al., 2011).
The screening of the mutations observed in the five cases 
of the discovery panel into an extended panel of cases has 
shown that only very few of these mutations display some 
minimal degree of recurrence, even when the entire gene is 
analyzed. This outcome appears different from that obtained 
in other malignancies, e.g., in DLBCL, where an analogous 
approach has led to the identification of a few highly recur­
rent genetic lesions (Pasqualucci et al., 2011). This result may 
reflect the fact that the most significant alterations involved in 
CLL pathogenesis have already been identified, including 
del13q14 involving the DLEU2/MIR15-16 cluster, trisomy 
12, and del11q. Alternatively, the rarity in recurrence may re­
flect the relationship of the observed lesions in functional 
pathways that are not presently recognized. One example in JEM Vol. 208, No. 7 
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studies were performed on the biopsy used for RS diagnosis. Biological sam­
ples from the paired CLL phase were available in 45 (77.5%) cases.
The clinical and biological characteristics of the consecutive series of 
newly diagnosed and previously untreated CLL (n = 120) are summarized in 
Table S6. After a median follow up from diagnosis for living patients of   
70.3 mo, the 5 yr­treatment free survival probability of the CLL cohort was 
60.0% and the 5­yr overall survival probability was 83.3%. The clinical and 
biological characteristics of the chemorefractory CLL cohort (n = 48) are 
summarized in Table S9. The median overall survival from chemorefractori­
ness was 1.6 yr. The clinical and biological characteristics of the RS cohort   
(n = 58) are summarized in Table S8. The median overall survival from RS 
transformation was 1.1 yr.
The study was approved by the Institutional Review Board of Columbia 
University and by the Ethical Committee of the Azienda Ospedaliera Maggiore 
della Carità di Novara, Amedeo Avogadro University of Eastern Piedmont.
IGHV mutational status. IGHV mutational status was performed as previ­
ously reported (Rossi et al., 2009). PCR products were directly sequenced 
with  the ABI  PRISM  BigDye Terminator  v1.1  Ready  Reaction  Cycle   
Sequencing kit (Applied Biosystems) using the ABI PRISM 3100 Genetic 
Analyzer (Applied Biosystems). Sequences were aligned to the ImMuno­
GeneTics sequence directory and considered mutated if homology to   
the corresponding germline gene was <98% (Damle et al., 1999; Hamblin   
et al., 1999).
FISH analysis. The following probes were used for FISH analysis of CLL 
and RS cases: LSID13S319, CEP12, LSIp53, LSIATM, LSI IGH/BCL2, 
LSI IGH/CCND1, LSI BCL6, LSI IGH/MYC/CEP8, MYC break­apart, 
LSI N­MYC, CEP2, CEP3, CEP11, CEP18, CEP19 (Abbott); a BCL­3 split 
signal probe (Dako); 6q21/­satellite (Kreatech Biotechnology); BAC clones 
373L24­REL, 440P05­BCL11A, RP11­177O8­BIRC3. The detailed proto­
col used for FISH studies is described elsewhere (Rossi et al., 2009).
Whole-exome capture  and massively parallel sequencing. Whole­
exome capture and next generation sequencing of the five CLL tumor/normal 
DNA samples were performed using the NimbleGen Sequence Capture 
2.1M Human Exome Array and the 454 Genome Sequencer FLX instru­
ment, according to the manufacturer’s protocol. The array features oligonu­
cleotides for 180,000 coding exons and 551 miRNA exons, corresponding 
to 85% of nonrepetitive sequences in the CCDS database (total size of tar­
get region, 34 Mb). The resulting target­enriched pool was amplified and 
subjected to high­throughput sequencing on the Genome Sequencer FLX 
Instrument of 454 Life Sciences using 2 PicoTiterPlate runs per sample (1 
million  reads/plate,  at  400­bp  reads). All  procedures  were  performed  at 
Roche and 454 Life Sciences.
454 sequencing data analysis. The computational pipeline used for the 
analysis of the deep sequencing data is reported in Fig. S1.
The sequencing reads obtained from the Roche FLX454 Sequencer 
were aligned to the human reference genome (National Center for Biotech­
nology Information build 36; hg18 assembly) with the Genome Sequencer 
Reference Mapper, version 2.3 (Roche). This application discards sequencing 
reads aligning to multiple positions of the reference sequence. Furthermore, 
because duplicate reads of a single DNA origin are a known potential artifact 
of the emulsion PCR step, groups of reads mapping to the same basepair of 
the reference sequence are counted as a single read in the subsequent com­
putation of variants.
The alignments of the uniquely mapped reads to the reference genome 
were used to define the genetic variants in the CLL tumor and normal DNAs 
as single base­pair substitutions, small insertions, and small deletions (indels). 
The Mapper application declares the presence of a variant allele with high­
confidence, if there are at least three nonduplicate reads harboring the variant 
(two in one sense and one in the opposite). Variant candidates in tumor samples 
were identified with the GSMapper software, using high confidence variant 
detection method. Germline variants were filtered using a less conservative 
From a clinical standpoint, NOTCH1 mutations cluster 
with CLL subgroups that are currently scored at extremely 
high risk because of TP53 disruption, refractoriness to fluda­
rabine, or transformation to RS. In the context of these highly 
unfavorable clinical settings, the appearance or selection of 
NOTCH1 mutations during disease progression has diagnos­
tic and therapeutic implications. The detection of these muta­
tions at the subclonal level using high sensitivity methods, 
such as the ultradeep next generation sequencing shown in 
Fig. 5 b, Fig. S4, and Fig. S5, may provide an objective and 
measurable biomarker for the early detection of the risk of 
progression or chemorefractoriness and therefore influence 
the clinical management of CLL. The validity of this attractive 
hypothesis needs to be explored by dedicated studies aimed at 
assessing the role of NOTCH1 as a predictor of RS and/or 
chemorefractoriness  at  the  time  of  CLL  diagnosis.  Finally, 
NOTCH1 represents a well­established therapeutic target with 
some drugs already available, such as those inhibiting its enzy­
matic conversion to active transcription factor, and others   
under active development (Real et al., 2009). Our results add 
CLL to the cadre of common diseases in which these drugs 
should be tested for their efficacy alone or in combination 
with available therapeutic regimens.
MATERIALS AND METHODS
Patients. Samples from 5 newly diagnosed and previously untreated CLL 
patients (discovery panel) were obtained from the Division of Hematology, 
Department  of  Clinical  and  Experimental  Medicine, Amedeo Avogadro   
University of Eastern Piedmont, as frozen peripheral blood mononuclear 
cells isolated by Ficoll­Paque gradient centrifugation. Diagnosis of CLL was 
based on IWCLL­NCI Working Group criteria and confirmed by a flow cytom­
etry score >3 (Hallek et al., 2008). In all cases, the fraction of tumor cells 
corresponded to >80%, as assessed by FACS analysis of CD19/CD5 expres­
sion. Matched normal DNA was obtained from peripheral blood granulo­
cytes that had been shown to be devoid of tumor cells by PCR analysis of 
patient­specific IGHV­D­J rearrangements. The clinical and biological char­
acteristics of cases belonging to the discovery panel are summarized in Table S1. 
Patients were representative of the two major immunogenetic subgroups of 
CLL (IGHV mutated, two cases; IGHV unmutated, three cases), and har­
bored common CLL­associated genetic abnormalities.
The screening panel used to assess the recurrence of mutations affecting 
genes that were identified through WES was composed of 48 newly diag­
nosed and previously untreated CLL patients provided by Amedeo Avogadro 
University of Eastern Piedmont. In all cases, the fraction of tumor cells cor­
responded to >80%, as assessed by FACS analysis of CD19/CD5 expression. 
Matched normal DNA was obtained for all cases from purified granulocytes 
or saliva and was confirmed to be devoid of tumor­derived material by PCR 
analysis of tumor­specific IGHV­D­J rearrangements. The clinical and bio­
logical characteristics of cases belonging to the screening panel are summa­
rized in  Table S5. Patients were representative of the two major immunogenetic 
subgroups of CLL (IGHV mutated, 24 cases; IGHV unmutated, 24 cases).
The prevalence of NOTCH1 mutations was further assessed in 3 clinical 
CLL panels representative of different disease phases, and including a consec­
utive series of newly diagnosed and previously untreated CLL (n = 120, ex­
tension panel), a cohort of chemorefractory CLL (n = 48), and a cohort of 
CLL transformed to RS (n = 58). Diagnosis of chemorefractoriness was ac­
cording to guidelines (Hallek et al., 2008). Diagnosis of RS was based on the 
histology of lymph node or extranodal tissue excisional biopsies. After insti­
tutional pathological review, all RS cases were classified as DLBCL according 
to the World Health Organization Classification of Tumours of the Hemato­
poietic and Lymphoid Tissues (Swerdlow, 2008). In all RS cases, molecular 1398 The CLL coding genome | Fabbri et al.
Purified  amplicons were  sequenced  by  conventional  Sanger method 
(Genewiz, Inc.) and compared with the corresponding germline sequences 
using the Mutation Surveyor Version 2.41 software package (SoftGenetics) 
after automated and/or manual curation. All variants were sequenced from 
both strands on independent PCR products obtained from high molecular 
weight genomic DNA. Synonymous mutations, previously reported poly­
morphisms, and changes present in the matched normal DNA, which was 
available for all samples, were removed from the analysis. To rule out the pos­
sibility of contamination across samples, DNA of selected RS cases harboring 
the highly recurrent CT(7544–7545) NOTCH1 mutation was re­extracted 
from the original tissue biopsy and retested in an independent laboratory, 
which confirmed the presence of the mutation.
Copy number analysis by high-density SNP array analysis. Genome­
wide DNA profiles were obtained from high molecular weight tumor and 
normal genomic DNA of the five CLL cases of the discovery panel using the 
Genome­Wide Human SNP Array 6.0 (Affymetrix). In brief, DNA was re­
striction enzyme digested, ligated, PCR­amplified, purified, labeled, frag­
mented, and hybridized to the arrays according to the manufacturer’s 
instructions. Data analysis was performed as previously described (Mullighan 
et al., 2007; Pounds et al., 2009).
RNA extraction and gene expression profile analysis. Adequate mate­
rial for extraction of RNA was available for three of the five CLL discovery 
cases, which were characterized by gene expression profile analysis. Total 
RNA extraction was performed by TRIzol (Invitrogen) following the man­
ufacturer’s instruction. Gene expression profile analysis of normal mature   
B cells (naive, memory, centroblasts, and centrocytes) and primary CLL cases 
was performed using Affymetrix HG­U133Plus 2.0 arrays. The cRNA was 
labeled and hybridized to the array according to the manufacturer’s protocol. 
The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using 
Affymetrix  default  analysis  settings  and  global  scaling  as  normalization 
method. Probe sets that had a mean (mu) <50, or a coefficient of variation 
(CV) <0.3, as assessed in a panel of 259 independent B cell–related gene ex­
pression profiles analyzed on the same array, were filtered out and considered 
not informative. Genes found mutated in the WES analysis were considered 
expressed if the corresponding probes were called “Present” in the CLL case 
carrying the mutation and/or in >90% of CLL cases from an independent 
panel hybridized to the same platform (n = 16).
Backtracking of RS-associated NOTCH1 mutation in the paired 
CLL diagnostic sample through 454-ultradeep sequencing. Oligo­
nucleotides containing the NOTCH1 specific sequences, along with the 10­
bp MID tag and amplicon library A and B sequencing adapters, were used to 
amplify the 349­bp target region of NOTCH1 exon 34 carrying the recur­
rent NOTCH1 mutation CT(7544–7545), P2515fs (see Results) in the 
CLL and RS phases from case 63. PCR primers and conditions are available 
upon request. Purified PCR products were quantitated, diluted, pooled, and 
amplified by emulsion PCR. The obtained amplicon library was subjected to 
ultradeep sequencing on the Genome Sequencer Junior instrument (454 Life 
Sciences),  according  to  the  manufacturer’s  instructions. The  obtained  se­
quencing reads were mapped to the reference sequence by Amplicon Variant 
Analyzer (Roche).
To identify subclonal variants in the CLL phase, we used the Back­
Tracker algorithm, developed in the Rabadan laboratory at Columbia Uni­
versity. We used the long­read component of BWA aligner (Li and Durbin, 
2010) to map the reads to the NOTCH1 reference genome (hg18). Next,   
using in­house developed software for variant detection, we compiled a list 
of substitutions, insertions, and deletions. Positions with Phred score below 
30 were removed. For deletions, we assigned the mean Phred score of the 
neighboring mapped positions. Excluding variants not seen in reads mapped 
to both forward and reverse strands, we fitted a negative binomial or Luria­
Delbruck distribution to variant depths, for which we applied a nonlinear 
least square fit to values larger than one. Unlike the approach presented by 
Campbell et al. (Campbell et al., 2008), homo­polymers were not eliminated 
approach (presence in ≥1 read) and by comparison with common SNPs re­
ported  in  the  National  Center  for  Biotechnology  Information  database.   
Using this observation, one can predict the sensitivity of the high­confidence 
criteria to detect heterozygous variant alleles in a sample containing 100% 
cancer genetic material as the fraction of sites covered with a depth of at 
least 6. Assuming that the two alleles of a heterozygous variant are covered 
with equal probability, a more precise prediction for the sensitivity to detect 
such variants is given by the high­confidence coverage (HCC) computed by 
the formula:
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where Nk corresponds to the number of basepairs covered by k sequencing 
reads and NT corresponds to the total number of basepairs covered.
Variants obtained by the high­confidence criterion of the Mapper ap­
plication were filtered further for nonsilent exonic mutations and mutations 
affecting a nucleotide within 4 nt of a consensus splice site. Furthermore, 
germline variants reported in publicly available databases (dbSNP, Ensembl 
Database, and UCSC Genome Browser) and/or identified in the paired nor­
mal DNAs were removed. Finally, variants caused by known systematic errors 
of the 454 sequencing technology (small indels affecting homopolymer 
repeats) and variants below the sensitivity of direct Sanger sequencing (i.e., 
observed in <20% of the reads), were also discarded.
Validation of candidate somatic mutations by Sanger sequencing. 
Candidate nonsilent somatic mutations were subjected to validation by con­
ventional  Sanger­based  resequencing  analysis  of  PCR  products  obtained 
from both normal and tumor high molecular weight genomic DNA using 
primers specific for the exon encompassing the variant. The sequences sur­
rounding the genomic locations of the candidate tumor­specific nonsilent 
mutations identified through WES were obtained from the UCSC Human 
Genome database (validation phase). The validation screen allowed us to 
eliminate additional private polymorphisms that had been missed by the next 
generation sequencing approach, presumably because of low coverage of the 
normal sample, as well as false positives caused by errors introduced during 
the sequencing procedure and/or by mapping errors, as it may occur in the 
case of repetitive regions or highly homologous regions in the genome. Con­
firmed nonsilent mutations were tested for their functional consequences in 
silico  by  using  the  PolyPhen­2  (polymorphism  phenotyping)  algorithm, 
which is based on structure/sequence conservation.
Mutation screening of identified genes. The complete coding sequences 
and exon/intron junctions of genes identified through the WES approach, 
including  NOTCH1  (under  GenBank/EMBL/DDBJ  accession  no.   
NM_017617.2), were analyzed in a larger dataset (screening panel, n = 48 
CLL cases) by PCR amplification and direct sequencing of whole genome 
amplified DNA obtained from two independent aliquots of high molecular 
weight genomic DNA (12 ng each) using the REPLI­g Mini kit (QIAGEN).
Sequences for all annotated exons and flanking introns were retrieved 
from the UCSC Human Genome database, using the corresponding mRNA 
accession no. as a reference. PCR primers, located ≥50 bp upstream or down­
stream to target exon boundaries, were either derived from previously pub­
lished studies or designed in the Primer 3 program, and filtered using UCSC 
In Silico PCR to exclude pairs yielding more than a single product. All PCR 
primers and conditions are available upon request. The oligonucleotides used 
for the validation phase produced PCR products and chromatograms evalu­
able in 99.3% of the target regions in the 5 CLL cases belonging to the dis­
covery panel. The vast majority of the oligonucleotides used for the screening 
phase (98%) yielded PCR products and high quality sequencing in 40 or 
more of the 48 screening samples. The NOTCH1 gene was also screened 
in an independent panel of 120 CLL diagnostic samples, 58 RS cases, and 
48  chemorefractory  CLL.  NOTCH2  (accession  no.  NM_024408.3)  and 
FBXW7 (accession no. NM_033632.2) were screened in 32 RS cases. All 
PCR primers and conditions are available upon request.JEM Vol. 208, No. 7 
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